A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

The Lancet Respiratory Medicine

Volumn 5, Issue 10, 2017, Pages 806-815

  Birring, Surinder S ^a   Wijsenbeek, Marlies S ^b   Agrawal, Sanjay ^c   van den Berg, Jan W K ^d   Stone, Helen ^e   Maher, Toby M ^f,g   Tutuncu, Ahmet ^h   Morice, Alyn H ⁱ  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c GLENFIELD HOSPITAL   (United Kingdom)

^d ISALA HOSPITAL   (Netherlands)

^e UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h Patara Pharma   (United States)

ⁱ CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CROMOGLYCATE DISODIUM; PA 101; PLACEBO; ANTIASTHMATIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC COUGH; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEFECATION URGENCY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; HEADACHE; HUMAN; HYPESTHESIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; OROPHARYNX PAIN; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREMOR; UNITED KINGDOM; XEROSTOMIA; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; NEBULIZER; PATHOPHYSIOLOGY; PROOF OF CONCEPT; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTI-ASTHMATIC AGENTS; CHRONIC DISEASE; COUGH; CROMOLYN SODIUM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NETHERLANDS; PILOT PROJECTS; PROOF OF CONCEPT STUDY; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

EID: 85028941654     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30310-7     Document Type: Article

References (66)

1. Raghu, G, Collard, HR, Egan, JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
2. Raghu, G, Weycker, D, Edelsberg, J, Bradford, WZ, Oster, G, Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174 (2016), 810–816.
3. Ryerson, CJ, Abbritti, M, Ley, B, Elicker, BM, Jones, KD, Collard, HR, Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 16 (2011), 969–975.
4. Key, AL, Holt, K, Hamilton, A, Smith, JA, Earis, JE, Objective cough frequency in idiopathic pulmonary fibrosis. Cough, 6, 2010, 4.
5. Swigris, JJ, Stewart, AL, Gould, MK, Wilson, SR, Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes, 3, 2005, 61.
6. Faruqi, S, Murdoch, RD, Allum, F, Morice, AH, On the definition of chronic cough and current treatment pathways: an international qualitative study. Cough 10 (2014), 5–13.
7. McGarvey, LP, Forsythe, P, Heaney, LG, MacMahon, J, Ennis, M, Bronchoalveolar lavage findings in patients with chronic nonproductive cough. Eur Respir J 13 (1999), 59–65.
8. Overed-Sayer, C, Rapley, L, Mustelin, T, Clarke, DL, Are mast cells instrumental for fibrotic diseases?. Front Pharmacol, 4, 2013, 174.
9. Cox, JS, Beach, JE, Blair, AM, et al. Disodium cromoglycate (Intal®). Adv Drug Res 5 (1970), 115–196.
10. Storms, W, Kaliner, MA, Cromolyn sodium: fitting an old friend into current asthma treatment. J Asthma 42 (2005), 79–89.
11. Bernstein, IL, Cromolyn sodium. Chest 87:1 suppl (1985), 68–73S.
12. Maher, SA, Birrell, MA, Baker, KE, et al. Cromoglycate: breathing life into an old asthma drug. Eur Respir J, 46(suppl 59), 2015 PA1017 (abstr).
13. Yang, Y, Lu, JYL, Wu, X, et al. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 86 (2010), 1–5.
14. Ohshiro, H, Tonai-Kachi, H, Ichikawa, K, GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem Biophys Res Commun 365 (2008), 344–348.
15. Vieria dos Santos, R, Magerl, M, Martus, M, et al. Topical sodium cromoglycate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 162 (2010), 674–676.
16. Keller, M, Schierholz, J, Have inadequate delivery systems hampered the clinical success of inhaled disodium cromoglycate? Time for reconsideration. Expert Opin Drug Deliv 8 (2011), 1–17.
17. Leaker, BR, Barnes, PJ, Jones, CR, Tutuncu, A, Singh, D, Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol 79 (2015), 492–500.
18. Knoch, M, Keller, M, The customized electronic nebulizer: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv 2 (2005), 377–390.
19. Birring, SS, Fleming, T, Matos, S, Rai, AA, Evans, DH, Pavord, ID, The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 31 (2008), 1013–1018.
20. Ryan, NM, Birring, SS, Gibson, PG, Gabapentin for refractory chronic cough: a randomized, double blind, placebo-controlled trial. Lancet 380 (2012), 1583–1589.
21. Boulet, LP, Coeytaux, RR, McCroy, DC, et al. Tools for assessing outcomes in studies of chronic cough. Chest Guideline and Expert Panel Report. Chest 147 (2015), 804–814.
22. Birring, SS, Prudon, B, Carr, AJ, Singh, SJ, Morgan, MDL, Pavord, ID, Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 58 (2003), 339–343.
23. Raj, AA, Pavord, DI, Birring, SS, Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire?. Handb Exp Pharmacol 187 (2009), 311–320.
24. Patel, AS, Siegert, RJ, Keir, GJ, et al. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 107 (2013), 1438–1443.
25. Miller, MR, Hankinson, J, Brusasco, V, et al. Standardisation of spirometry. ATS/ERS Task Force: standardisation of lung function testing. Eur Respir J 26 (2005), 319–338.
26. Kelsall, A, Houghton, LA, Jones, H, Decalmer, S, McGuinneess, K, Smith, JA, A novel approach to studying the relationship between subjective and objective measures of cough. Chest 139 (2011), 569–575.
27. Smith, J, Kitt, M, Sher, M, Butera, P, Ford, A, Tackling the burden of chronic cough: a dose escalation study of AF-219. Eur Respir J, 48(suppl 60), 2016 OA1976 (abstr).
28. Raj, AA, Birring, SS, Clinical assessment of chronic cough severity. Pulm Pharmacol Ther 20 (2007), 334–337.
29. Charmberlain-Mitchel, SA, Garrod, R, Clark, L, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax 72 (2017), 129–136.
30. Canning, BJ, Chang, AB, Bolser, D, et al. Anatomy and neurophysiology of cough. Chest guideline and expert panel report. Chest 146 (2014), 1633–1648.
31. Mazzone, SB, Undem, BJ, Vagal afferent innervation of the airways in health and disease. Physiol Rev 96 (2016), 975–1024.
32. Raghu, G, Freudenberger, TD, Yang, S, et al. High prevalence of abnormal acid gastroesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 27 (2006), 136–142.
33. Van Manen, MJG, Birring, SS, Vancheri, C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev 25 (2016), 278–286.
34. Hope-Gill, BD, Hilldrup, S, Davies, C, Newton, RP, Harrison, NK, A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168 (2003), 995–1002.
35. Kinder, BW, Brown, KK, Schwarz, MI, Ix, JH, Kervitsky, A, King, TE Jr, Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 133 (2008), 226–232.
36. Birring, SS, Parker, D, McKenna, S, et al. Sputum eosinophilia in idiopathic pulmonary fibrosis. Inflamm Res 54 (2005), 51–56.
37. Madison, JM, Irwin, RS, Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med 11 (2005), 412–416.
38. Andersson, CK, Andersson-Sjoland, A, Mori, M, et al. Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis. Respir Res, 12, 2011, 139.
39. Kawanami, O, Ferrans, VJ, Fulmer, JD, Crystal, RG, Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab Invest 40 (1979), 717–734.
40. Lavinka, PC, Dong, X, Molecular signaling and targets from itch: lessons for cough. Cough, 9, 2013, 8.
41. Cha, S-I, Chang, CS, Kim, EK, et al. Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis. Histopathology 61 (2012), 98–106.
42. Inoue, Y, King, TE, Tinkle, SS, Dockstader, K, Newman, LS, Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol 149 (1996), 2037–2054.
43. Wygrecka, M, Dahal, BK, Kosanovic, D, et al. Mast cells and fibroblasts work in concert to aggregate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-α/Raf-1/p44/42 signaling pathway. Am J Pathol 182 (2013), 2094–2108.
44. Noble, PW, Albera, C, Bradford, WZ, et al., for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
45. Azuma, A, Taguchi, Y, Ogura, T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res, 12, 2011, 143.
46. Van Manen, Birring, SS, Vancheri, C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 193, 2016, A2696.
47. Horton, MR, Santiopietro, V, Mathew, L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med 157 (2012), 398–406.
48. Ye, Q, Chen, B, Tong, Z, et al. Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease. Eur Respir J 28 (2006), 824–831.
49. Cata, JP, Weng, HR, Dougherty, PM, The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res 1229 (2008), 100–110.
50. Rochwerg, B, Neupane, B, Zhang, Y, et al. Treatment of idiopathic pulmonary fibrosis: a network meta analysis. BMC Med, 14, 2016, 18.
51. Lutherer, LO, Nugent, KM, Schoettle, BW, et al. Low-dose oral interferon α possibly retards the progression of idiopathic pulmonary fibrosis and alleviates associated cough in some patients. Thorax 66 (2011), 446–447.
52. Kilduff, CE, Counter, MJ, Thomas, GA, Harrison, NK, Hope-Gill, BD, Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study. Cough, 10, 2014, 4.
53. Mensinga, T, Diamant, Z, Qude-Elberink, JNG, Tutuncu, A, Improved systemic bioavailability of cromolyn sodium using inhaled PA101 via eFlow nebulizer. Am J Respir Crit Care Med, 195, 2017, A3476 (abstr).
54. Moqbel, R, Walsh, GM, Macdonald, AJ, Kay, B, Effect of disodium cromoglycate on activation of human eosinophils and neutrophils following reversed (anti-IgE) anaphylaxis. Clin Allerg 16 (1986), 73–83.
55. Shapiro, GG, König, P, Cromolyn sodium: a review. Pharmacotherapy 5 (1973), 156–170.
56. Galli, SJ, Tsai, M, IgE and mast cells in allergic disease. Nat Med 18 (2013), 693–704.
57. Dixon, M, Jackson, DM, Richards, IM, The action of sodium cromoglycate on ‘C' fibre endings in the dog lung. Br J Pharmacol 70 (1980), 11–13.
58. Hemmati, AA, Nazari, Z, Motlagh, ME, Goldasteh, S, The role of sodium cromolyn in treatment of paraquat-induced pulmonary fibrosis in rat. Pharmacol Res 46 (2002), 229–234.
59. Harchegani, AL, Hemmati, AA, Nili-Ahmadabadi, Darabi, B, Shabib, S, Cromolyn sodium attenuates paraquat-induced lung injury by modulation of proinflammatory cytokines. Drug Res 67 (2017), 283–288.
60. Choi, JS, Kim, JK, Yang, YJ, et al. Identification of cromolyn sodium as an anti-fibrotic agent targeting both hepatocytes and hepatic stellate cells. Pharmacol Res 102 (2015), 176–183.
61. Polaniyandi Selvaraj, S, Watanabe, K, Ma, M, et al. Involvement of mast cells in the development of fibrosis in rats with postmyocarditis dilated cardiomyopathy. Biol Pharm Bull 28 (2005), 2128–2132.
62. Veerappan, A, Reid, AC, O'Conner, N, et al. Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. Am J Physiol Renal Physiol 302 (2012), F192–F204.
63. Chen, L, Schementi, ME, Ranzer, MJ, Wilgus, TA, DiPietro, LA, Blockade of mast cell activation reduces cutaneous scar formation. PLoS One, 9, 2014, e85226.
64. Moroni, M, Porta, C, Gualtieri, G, Nastasi, G, Tinelli, C, Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients. Br J Cancer 74 (1996), 309–311.
65. Veerappan, A, O'Conner, NJ, Brazin, J, et al. Mast cells: a pivotal role in pulmonary fibrosis. DNA Cell Biol 32 (2013), 206–218.
66. Doherty, MJ, Mister, R, Pearson, MG, Calverly, PMA, Capsaicin induced cough in cryptogenic fibrosing alveolitis. Thorax 55 (2000), 1028–1032.